Underfunding of chondroprotectors: A therapeutic gap?
DOI:
https://doi.org/10.30827/ars.v62i3.16882Keywords:
Osteoarthritis, diacerein, glucosamine, chondroitin, drug costsAbstract
Introduction: The use of chondroprotectives was presented as a better strategy aimed at the treatment of osteoarthritis due to its attributed chondromodulatory effect and greater safety. However, their use is disputed.
The aim of the present work was to review and compare the chondroprotectives in terms of efficacy (on pain, function and joint narrowing), safety and economic profitability in the management of osteoarthritis.
Methodology: A bibliographic search of the literature published has been carried out. The databases used were Medline and Scopus. The medical guide of the ESCEO (European Society for Clinical and Economic Aspects of Osteoathritis), the epidemiological study of the Spanish Society of Rheumatology and the technical sheets of medicines of the Spanish Agency of Medicines were reviewed.
Results: A total of 152 articles were identified with the search algorithms used and the inclusion/exclusion criteria applied. After having read titles and abstracts, 79 were excluded because they did not conform to the required methodological quality or to treat other applications other than osteoarthritis. After reading the rest of the articles in their entirety, 36 articles were finally selected that were adapted to the objective of this work.
Conclusions: The clinical trials that evaluated diacerein and chondroitin sulfate had highly variable designs that could justify the variability of the results obtained. With the underfunding of these drugs by the SNS, the expected savings could be reversed by the use of more expensive healthcare resources in the future given the short-term focus of permanent therapies.
Downloads
References
Fidelix TSA, Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 10;(2):CD005117. DOI: 10.1002/14651858.CD005117.pub3
Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015; 38(3):245–52. DOI: 10.1007/s40264-015-0266-z
Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015; 28;1:CD005614. DOI: 10.1002/14651858.CD005614.pub2
Honvo G, Reginster J-Y, Rabenda V, Geerinck A, Mkinsi O, Charles A, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl 1):65–99. DOI: 10.1007/s40266-019-00662-z
Bartels EM, Bliddal H, Schøndorff PK, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2010; 18(3):289–96. DOI: 10.1016/j.joca.2009.10.006
Safiri S, Kolahi A-A, Smith E, Hill C, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(6):819–28. DOI: 10.1136/annrheumdis-2019-216515
Sociedad Española de Reumatología. Prevalencia de Enfermedades Reumáticas en Población Española. Estudio EPISER [Internet]. 2016. Available from: https://www.ser.es/se-ha-presentado-el-estudio-episer-2016-en-la-sede-del-ministerio-de-sanidad-consumo-y-bienestar-social/
Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging. 2016; 33(2):75–85. DOI: 10.1007/s40266-016-0347-4.
Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–50. DOI: 10.1016/j.semarthrit.2019.04.008
FICHA TECNICA CONDROSULF 400 mg CAPSULAS [Internet]. [cited 2020 Oct 17]. Available from: https://cima.aemps.es/cima/dochtml/ft/64547/FichaTecnica_64547.html
Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006; 25;166(17):1899–906. DOI: 10.1001/archinte.166.17.1899
European Medicines Agency. PRAC re-examines diacerein and recommends that it remain available with restrictions [Internet]. London: EMA; 2014 Mar p. 2. Report No.: EMA/133894/2014. Available from: https://www.ema.europa.eu/en/news/prac-re-examines-diacerein-recommends-it-remain-available-restrictions#:~:text=The%20EMA’s%20Pharmacovigilance%20Risk%20Assessment,and%20effects%20on%20the%20liver.
Martel-Pelletier J, Raynauld J-P, Mineau F, Abram F, Paiement P, Delorme P, et al. Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study. Arthritis Res Ther. 2017 20;19(1):169. DOI: 10.1186/s13075-017-1377-y
Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001; 27;357(9252):251–6. DOI: 10.1016/S0140-6736(00)03610-2
Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994; 37(4):529–36. DOI: 10.1002/art.1780370413
AEMPS. FICHA TECNICA GLUCOSAMINA CINFA 1500 mg POLVO PARA SOLUCION ORAL EFG [Internet]. 2020 Mar [cited 2020 Nov 21]. Available from: https://cima.aemps.es/cima/dochtml/ft/68105/FichaTecnica_68105.html
FICHA TECNICA GALAXDAR 50 mg CAPSULAS DURAS [Internet]. [cited 2020 Oct 18]. Available from: https://cima.aemps.es/cima/dochtml/ft/64554/FT_64554.html
Almezgagi M, Zhang Y, Hezam K, Shamsan E, Gamah M, Al-Shaebi F, et al. Diacerein: Recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother. 2020; 25;131: 110594. DOI: 10.1016/j.biopha.2020.110594
Morita M, Yamada K, Date H, Hayakawa K, Sakurai H, Yamada H. Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan. Biol Pharm Bull. 2018; 1;41(2):163–71. DOI: 10.1248/bpb.b17-00556
Shin K, Kim JW, Moon KW, Yang JA, Lee EY, Song YW, et al. The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clin Ther. 2013; 35(4):431–9. DOI: 10.1016/j.clinthera.2013.02.009
Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014; 78(3):184–7. DOI: 10.1016/j.maturitas.2014.04.015
Zheng W-J, Tang F-L, Li J, Zhang F-C, Li Z-G, Su Y, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China. APLAR Journal of Rheumatology. 2006;9(1):64–9. DOI: 10.1111/j.1479-8077.2006.00167.x
Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S, Thai Study Group. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage. 2007; 15(6):605–14. DOI: 10.1016/j.joca.2007.02.021
Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. Int J Rheum Dis. 2012;15(1):69–77. DOI: 10.1111/j.1756-185X.2011.01648.x
Dougados M, Nguyen M, Berdah L, Maziéres B, Vignon E, Lequesne M, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001; 44(11):2539–47. DOI: 10.1002/1529-0131(200111)44:11<2539::aid-art434>3.0.co;2-t
Vignon E. [Results of the ECHODIAH clinical trial on hip arthrosis]. Presse Med. 2002; 12;31(1 Pt 2):7–9.
European Medicines Agency. Assessment report for diacerein containing medicinal products [Internet]. 2014. Available from: https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-prac-assessment-report_en.pdf
Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis. 2004; 63(12):1611–7. DOI: 10.1136/ard.2003.019703
Hochberg MC, Martel-Pelletier J, Monfort J, Möller I, Castillo JR, Arden N, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016; 75(1):37–44. DOI: 10.1136/annrheumdis-2014-206792
Simental-Mendía M, Sánchez-García A, Vilchez-Cavazos F, Acosta-Olivo CA, Peña-Martínez VM, Simental-Mendía LE. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int. 2018; 38(8):1413–28. DOI: 10.1007/s00296-018-4077-2
Zhu X, Sang L, Wu D, Rong J, Jiang L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018; 6;13(1):170. DOI: 10.1186/s13018-018-0871-5
Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010; 16;341:c4675. DOI: 10.1136/bmj.c4675
Pelletier J-P, Raynauld J-P, Beaulieu AD, Bessette L, Morin F, de Brum-Fernandes AJ, et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016; 03;18(1):256. DOI: 10.1186/s13075-016-1149-0
Raynauld J-P, Pelletier J-P, Delorme P, Dodin P, Abram F, Martel-Pelletier J. Bone curvature changes can predict the impact of treatment on cartilage volume loss in knee osteoarthritis: data from a 2-year clinical trial. Rheumatology (Oxford). 2017; 01;56(6):989–98. DOI: 10.1093/rheumatology/kew504
Reginster J-YL, CONCEPT Investigation Group. CONCEPT provides robust evidence that chondroitin sulfate is superior to placebo and similar to celecoxib in the symptomatic management of osteoarthritis. Ann Rheum Dis. 2018;77(2):e11. DOI: 10.1136/annrheumdis-2017-212165
European Medicines Agency. Guideline of clinical investigation of medical products used in the treatment of Osteoarthritis [Internet]. London: EMA; 2020 Jan [cited 2020 Nov 2]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-used-treatment-osteoarthritis_en.pdf
Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002; 14;162(18):2113–23. DOI: 10.1136 / annrheumdis-2017-212165
Monfort J, Pujol J, Contreras-Rodríguez O, Llorente-Onaindia J, López-Solà M, Blanco-Hinojo L, et al. Effects of chondroitin sulfate on brain response to painful stimulation in knee osteoarthritis patients. A randomized, double-blind, placebo-controlled functional magnetic resonance imaging study. Med Clin (Barc). 2017; 21;148(12):539–47. DOI: 10.1016 / j.medcli.2016.12.036
Martel-Pelletier J, Farran A, Montell E, Vergés J, Pelletier J-P. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules. 2015; 6;20(3):4277–89. DOI: 10.3390/molecules20034277
Arden N, Blanco FJ, Bruyère O, Cooper C, Guermazi A, Hayashi D, et al. ESCEO. Atlas of Osteoarthritis (2nd Edition) [Internet]. Springer Healthcare; 2018. Available from: http://www.esceo.org/sites/esceo/files/pdf/Atlas%20of%20Osteoarthritis15032018.pdf
Bruyère O, Altman RD, Reginster J-Y. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016; 45(4 Suppl):S12-17. DOI: 10.1016/j.semarthrit.2015.11.011
Reginster J-Y, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017; 76(9):1537–43. DOI: 10.1136/annrheumdis-2016-210860
Agencia Española de Medicamento y Productos Sanitarios. Diacereína: la evaluación europea concluye que el balance beneficio-riesgo es desfavorable [Internet]. Madrid; 2013 Nov p. 3. (MUH (FV), 20/2013). Available from: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2013/docs/NI-MUH_FV_30-2013-diacereina.pdf?x27133
Rubio-Terrés C, Grupo del estudio VECTRA. [An economic evaluation of chondroitin sulfate and non-steroidal anti-inflammatory drugs for the treatment of osteoarthritis. Data from the VECTRA study]. Reumatol Clin. 2010; 6(4):187–95. DOI: 10.1016/j.reuma.2009.12.009
Lagnaoui R, Baumevielle M, Bégaud B, Pouyanne P, Maurice G, Depont F, et al. Less use of NSAIDs in long-term than in recent chondroitin sulphate users in osteoarthritis: a pharmacy-based observational study in France. Therapie. 2006; 61(4):341–6. DOI: 10.2515/therapie:2006063
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Ars Pharmaceutica (Internet)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
